Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

Published:2010-02 Issue:2 Volume:21 Page:376-381
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Wakelee H.A.,Patnaik A.,Sikic B.I.,Mita M.,Fox N.L.,Miceli R.,Ullrich S.J.,Fisher G.A.,Tolcher A.W.

Funder

Human Genome Sciences, Inc.

National Institutes of Health

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/21/2/376/922041/mdp292.pdf

Reference27 articles.

1. Death to the bad guys: targeting cancer via Apo2L/TRAIL;Bouralexis;Apoptosis,2005

2. Expression of TRAIL and TRAIL receptors in normal and malignant tissues;Daniels;Cell Res,2005

3. Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction;Koornstra;Eur J Cancer,2005

4. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors;Spierings;Clin Cancer Res,2003

5. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer;McCarthy;Clin Cancer Res,2005

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling;Antibodies;2024-07-09

2. Cellular functions, molecular signalings and therapeutic applications: Translational potential of deubiquitylating enzyme USP9X as a drug target in cancer treatment;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-05

3. Current and future prospective of caspases targeting in cancer therapy;Caspases as Molecular Targets for Cancer Therapy;2024

4. TRAIL-mediated signaling in bladder cancer: realization of clinical efficacy of TRAIL-based therapeutics in medical oncology;Medical Oncology;2023-07-11

5. Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy;Cells;2022-11-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3